uniQure NV
Closed
46.39 3.99
Overview
Share price change
24h
Min
46
Max
46.4
Income | -28M -81M |
|---|---|
Sales | 2.3M 5.8M |
EPS | -1.22 |
Profit margin | -1,387.759 |
Employees | 221 |
EBITDA | -34M -70M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +41.38% upside |
Next Earnings | 9 lis 2026 |
|---|
Market Cap | 429M 3.1B |
|---|---|
Previous open | 42.4 |
Previous close | 46.39 |
uniQure NV Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
uniQure NV Forecast
Price Target
By TipRanks
41.38% upside
12 Months Forecast
Average 65.63 USD 41.38%
High 80 USD
Low 46 USD
Based on 10 Wall Street analysts offering 12 month price targets foruniQure NV - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
